|
Prof Kanti Rai discusses advances that have been made in the treatment of chronic lymphocytic leukaemia (CLL). Key research presented at this years ASH congress has demonstrated that previously untreated patients who do not want or are unsuitable for chemotherapy can be successfully treated with a combination of rituximab and lenalidomide. In addition to this a number of studies have been presented which have confirmed FCR (fludarabine, cyclophosphamide and rituximab) as the most effective frontline treatment for CLL and there have also been positive results for new tyrosine kinase inhibitors used to treat patients who do not respond to FCR. Prof Rai also explains how the low toxicity levels of bendamustine makes it particularly suitable to treat elderly CLL patients, discusses the use of lenalidomide, elotuzumab or rituximab as maintenance treatment to help patients avoid further chemotherapy, speaks about the movement towards personalised medicines for CLL and looks ahead to the IWCLL (International Workshop on CLL) congress to be held in Texas on 28-30 October 2011.
|
Video Length: 0
Date Found: February 18, 2011
Date Produced:
|
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
|
www.ecancer.tv |
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
|
www.ecancer.tv |
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
|
www.ecancer.tv |
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
|
|
|
|
|
|
Featured Content
Featuring websites that enhance the internet user’s experience.
|